Enlivex (ENLV) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Enlivex Therapeutics Ltd. is inviting investors to an informative webinar on June 25, 2024, featuring updates on the company’s breakthrough immunotherapy product, Allocetra™, and insights from their CEO, Dr. Oren Hershkovitz. The webinar will highlight promising Phase I/II trial results for Allocetra™, showing significant pain reduction in severe knee osteoarthritis patients, and will also cover the company’s clinical program progress and financial status after a recent funding round.
For further insights into ENLV stock, check out TipRanks’ Stock Analysis page.